| 10/05 | PERKINELMER INC Management's Discussion and Analysis of Financial Condition and Result.. | AQ |
| 03/05 | PERKINELMER : Q1 Earnings Snapshot | AQ |
| 03/05 | PERKINELMER INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 03/05 | PerkinElmer Announces Financial Results for the First Quarter of 2022 | BU |
| 29/04 | PERKINELMER INC : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
| 28/04 | PERKINELMER : Showcases Leading Informatics Solutions and Strategic Services at Bio-IT Wor.. | PU |
| 28/04 | PerkinElmer Board Declares Quarterly Dividend | BU |
| 18/04 | PERKINELMER : Oxford Immunotec Debuts Global Immunology Services Offering at World Vaccine.. | PU |
| 14/04 | PERKINELMER : Scitara announces collaboration with PerkinElmer Informatics to create new m.. | PU |
| 12/04 | PerkinElmer Schedules Earnings Call for Tuesday, May 3, 2022 | BU |
| 08/04 | PERKINELMER : Showcases Expanded Technology and Solutions Portfolio to Accelerate Cancer R.. | PU |
| 07/04 | PerkinElmer Expands In Vivo Instruments Portfolio with Hands-free, High-throughput Vega.. | BU |
| 04/04 | PerkinElmer Introduces First Ready-to-use HTRF® and AlphaLISA® Assay Kits for CHO HCP I.. | BU |
| 01/04 | PERKINELMER INC : Regulation FD Disclosure (form 8-K) | AQ |
| 15/03 | PERKINELMER : Expands Salmonella Testing Portfolio with Solus One™ Detection Kit for.. | PU |
| 09/03 | PERKINELMER : Launches Innovative FT-IR Platform for Quality and Safety Testing of Wine, D.. | PU |
| 03/03 | PERKINELMER INC Management's Discussion and Analysis of Financial Condition and Result.. | AQ |
| 02/03 | PERKINELMER : and P1 Fuels team up to boost sustainable mobility through fossil-free fuels | PU |
| 02/03 | PERKINELMER : Launches ChemDraw® V21 Software, Empowering Researchers to Rapidly Create Ch.. | PU |
| 01/03 | PerkinElmer to Present at Upcoming Investor Conferences | BU |
| 10/02 | PerkinElmer to Present at Citi's 2022 Virtual Healthcare Conference | BU |
| 03/02 | PERKINELMER : to Showcase Expanded Life Science / Cell & Gene Therapy Portfolios and Autom.. | PU |
| 03/02 | U.S. Centers for Disease Control Guidance Includes EUROIMMUN Assay in its Two-Step Test.. | BU |
| 02/02 | PERKINELMER : and P1 Fuels team up to boost sustainable mobility through fossil-free fuels | PU |
| 01/02 | PERKINELMER : Q4 Earnings Snapshot | AQ |
| 01/02 | PERKINELMER : Q4 2021 Non-GAAP Reconciliations | PU |
| 01/02 | PERKINELMER : Announces Financial Results for the Fourth Quarter and Full Year of 2021 - F.. | PU |
| 01/02 | PERKINELMER INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 01/02 | PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021 | BU |
| 27/01 | PerkinElmer Board Declares Quarterly Dividend | BU |
| 11/01 | PERKINELMER : 2022 JPM Healthcare Conference Presentation | PU |
| 11/01 | PERKINELMER : Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1.. | PU |
| 11/01 | PERKINELMER INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 11/01 | PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February .. | BU |
| 2021 | PerkinElmer to Present Virtually at J.P. Morgan Healthcare Conference | BU |
| 2021 | PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Su.. | BU |
| 2021 | PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capabili.. | BU |
| 2021 | PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021 | BU |
| 2021 | PERKINELMER INC Management's Discussion and Analysis of Financial Condition and Result.. | AQ |
| 2021 | PerkinElmer to Present at 2021 Stifel Healthcare Conference | BU |
| 2021 | BioLegend, Inc. and subsidiaries Index to financial statements - Form 8-K/A | PU |
| 2021 | PERKINELMER INC Completion of Acquisition or Disposition of Assets, Financial Statemen.. | AQ |
| 2021 | PERKINELMER : Q3 Earnings Snapshot | AQ |
| 2021 | PerkinElmer Announces Financial Results for the Third Quarter of 2021 - Form 8-K | PU |
| 2021 | PERKINELMER INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | PerkinElmer Announces Financial Results for the Third Quarter of 2021 | BU |
| 2021 | PerkinElmer Releases 2021 Corporate Social Responsibility Report | BU |
| 2021 | PerkinElmer Board Declares Quarterly Dividend | BU |
| 2021 | PERKINELMER : Signals Research™ Suite Platform Integrates Scientific Data Silos and .. | PU |
| 2021 | PERKINELMER : Participates in NIST Program to Advance Cannabis and Hemp Testing Standardiz.. | PU |
| 2021 | PERKINELMER : and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-C.. | BU |
| 2021 | PERKINELMER : Collaborates With Leading Life Science Incubators LabCentral and MBC BioLabs.. | PU |
| 2021 | PERKINELMER : Schedules Earnings Call for Tuesday, November 2, 2021 | BU |
| 2021 | PERKINELMER : Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel | BU |
| 2021 | PERKINELMER : EUROIMMUN Anti-SARS-CoV-2 S1 Curve ELISA Receives FDA Emergency Use Authoriz.. | BU |
| 2021 | PERKINELMER : Introduces Next Generation Cell Image Analysis and Management Software Platf.. | PU |
| 2021 | PERKINELMER : Registration Statement on Form S-3 (Form 8-K) | PU |
| 2021 | PERKINELMER INC : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | PERKINELMER : Mount Sinai Health System and PerkinElmer Collaborate to Accelerate COVID-19.. | PU |
| 2021 | PERKINELMER : Completion of Acquisition or Disposition of Assets (Form 8-K) | PU |
| 2021 | PERKINELMER INC : Completion of Acquisition or Disposition of Assets, Creation of a Direct.. | AQ |
| 2021 | PERKINELMER : Completes Acquisition of Antibody and Reagent Leader BioLegend | BU |
| 2021 | PERKINELMER INC : Entry into a Material Definitive Agreement, Other Events (form 8-K) | AQ |
| 2021 | PERKINELMER : Prices Offering of Senior Notes | BU |
| 2021 | PERKINELMER : Introduces IndiScope™ Solution to Help Dairy Collection Points Test Mi.. | PU |
| 2021 | PERKINELMER INC : Entry into a Material Definitive Agreement, Termination of a Material De.. | AQ |
| 2021 | PERKINELMER : to Present at 2021 Baird Global Healthcare Conference | BU |
| 2021 | PERKINELMER INC : Entry into a Material Definitive Agreement, Creation of a Direct Financi.. | AQ |
| 2021 | PERKINELMER : Management's Discussion and Analysis of Financial Condition and Results of O.. | AQ |
| 2021 | PERKINELMER : to Acquire Antibody and Reagent Leader BioLegend Transformative deal signifi.. | PU |
| 2021 | PERKINELMER INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity .. | AQ |
| 2021 | PERKINELMER : to pay $5.25B for antibody maker BioLegend | AQ |
| 2021 | PERKINELMER : Q2 2021 Earnings Presentation | PU |
| 2021 | PERKINELMER : to Acquire BioLegend | PU |
| 2021 | PERKINELMER : BioLegend Acquisition Infographic | PU |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
